| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11141540 | ADAMIS PHARMS CORP | Syringe devices |
Oct, 2036
(13 years from now) | |
Symjepi is owned by Adamis Pharms Corp.
Symjepi contains Epinephrine.
Symjepi has a total of 1 drug patent out of which 0 drug patents have expired.
Symjepi was authorised for market use on 15 June, 2017.
Symjepi is available in solution;intramuscular, subcutaneous dosage forms.
Symjepi can be used as a method for administering a therapeutic dose of epinephrine.
The generics of Symjepi are possible to be released after 20 October, 2036.
Drugs and Companies using EPINEPHRINE ingredient
Market Authorisation Date: 15 June, 2017
Treatment: A method for administering a therapeutic dose of epinephrine
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
SYMJEPI family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic